Avantex Biotechnologies Inc.
  • About
    • Overview
    • Management & Directors
    • Disclaimer
  • Applications
    • Eye-Care Application
    • Lung Cancer Application
    • – Lung Cancer Problem
    • – Lung Cancer in China
    • Cannabis Applications
    • MRI Application
    • Published Research Papers
  • News
    • Industry News
    • Media Contact
  • Contact
    • Contact Information
  • Menu Menu
APPLICATIONS

Lung Cancer Application

The Avantex Solution
Avantex Biotechnologies’ Acufilic™ proprietary dual-drug delivery platform provides an efficacious therapeutic strategy to eradicate tumors. The platform combats multidrug resistance in cancer cells, resulting in reducing substantial tumor recurrence.Multi-ethnic group of scientists working inside a research laboratory. Test tubes, beakers, microscope, chart. They are conducting genetic science experiments for cancer research. They hold a chemotherapy drug in a yellow bag. Molecular structure on table.

Incorporation of immunotherapeutics in the forthcoming nanoformulations will provide further strengthening of our proprietary solution for the treatment of a full spectrum of non-small cell lung cancer treatment to benefit more patients worldwide.

Combination therapies and nano dual-drug delivery are two areas that have shown significant promise in medical treatment. The combined therapy of two or more drugs promotes synergism among the different drugs and suppresses drug resistance when working against diseases. Therapeutic effectiveness is further enhanced when combined with nano dual-drug delivery, providing designated synergy and considerably reducing the side effects of drugs. These two active research fields have recently been merged to further improve the efficacy of cancer and other medical therapeutics.

Avantex Biotechnologies has been actively developing nanoparticle platforms to concurrently deliver multiple types of drugs for combination chemotherapy and other medical therapies to provide maximum synergy.

  • Eye-Care Application
  • MRI Application
  • Lung Cancer Application
  • – Lung Cancer Problem
  • – Lung Cancer in China
  • Cannabis Applications
  • Published Research Papers

INDUSTRY NEWS

  • What to Expect From the Launch of Cannabis Edibles in CanadaDecember 31, 2019 - 12:00 pm
  • New Cannabis Products to Follow Edibles LegalizationSeptember 5, 2019 - 12:00 pm
  • Canada’s cannabis edibles, topicals market could be worth $2.7B a year after legalization: studyJune 3, 2019 - 12:00 pm
  • Scientists Are Racing to Make Weed As Easy to Drink as BeerMarch 26, 2019 - 8:00 am
  • Canopy Growth set to become the ‘global titan’ of cannabis: CIBC reportJanuary 21, 2019 - 12:00 pm
  • Popular Canadian pharmacy chain officially starts carrying medical cannabisJanuary 9, 2019 - 10:00 am

ABOUT
Overview
Management & Directors
Disclaimer

BIOTECH APPLICATIONS
Eye-Care Application
Lung Cancer Application
– Lung Cancer Problem
– Lung Cancer in China
Cannabis Applications
MRI Application
Research Papers

NEWS
Industry News
Media Contact

CONTACT
Contact Information

CONTACT
Nikita Chou, President
E: nchou@avantexbio.com
M: +1-778-888-3892

Ullrich Schade, VP Marketing
E: uschade@avantexbio.com
M: +1-604-644-4914

Branding by:
NextPhase Strategy

Scroll to top